Opus Genetics, Inc.

Stocks

IRD

US67577R1023

Market Closed - Nasdaq Other stock markets 06:00:00 17/06/26 am AEST			5-day change	1st Jan Change
3.900 ^USD	-0.38%		-3.23%	+94.03%

17/06	Opus Genetics, Inc. - Special Call
04/06	Guggenheim Initiates Opus Genetics at Buy With $16 Price Target	MT

Transcript : Opus Genetics, Inc. - Special Call

Published on 06/17/2026 at 06:50 am AEST

S&P Capital IQ

Presenter Speech
Benjamin Yerxa (Executives)

Good morning, and thank you for joining us today to delve into our gene therapy pipeline with a focus on our earlier-stage programs. As a reminder, this

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Opus Genetics, Inc.

17/06	Opus Genetics, Inc. - Special Call
04/06	Guggenheim Initiates Opus Genetics at Buy With $16 Price Target	MT
29/05	Opus Genetics reports inducement grants under Nasdaq listing rule	RE
21/05	Leerink Partners Initiates Opus Genetics at Outperform With $10 Price Target	MT
12/05	Opus Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
07/05	Opus Genetics Completes Enrollment In Cohort 1 Of Phase 1/2 OPGx-BEST1 Gene Therapy Study	CI
05/05	Opus Genetics Gene Therapy Accepted into FDA's Rare Disease Program	DJ
05/05	Opus Genetics Announces Fda Acceptance of Opgx-Lca5 into Rare Disease Evidence Principles Program	CI
01/05	B. Riley Adjusts Opus Genetics Price Target to $10 From $9, Maintains Buy Rating	MT
07/04	Opus Genetics, Inc. announced that it expects to receive $159.999994 million in funding from Oberland Capital Management LLC	CI
06/04	Opus Genetics Secures Up to $155 Million Financing From Oberland Capital	MT
06/04	Opus Genetics Inc announced strategic financing agreement with Oberland Capital Management LLC	RE
30/03	Cantor Fitzgerald Initiates Opus Genetics at Overweight With $15 Price Target	MT
16/03	Oppenheimer Initiates Opus Genetics at Outperform With $10 Price Target	MT
12/03	Wedbush Raises Price Target on Opus Genetics to $10 From $8, Keeps Outperform Rating	MT